Evidence map›Paper›PMID 28437477›Full record

ArticlePloS one2017

Outcomes after antiretroviral therapy during the expansion of HIV services in Haiti.

Margaret L McNairy, Patrice Joseph, Michelle Unterbrink, Stanislas Galbaud, Jean-Edouard Mathon, Vanessa Rivera, Deanna Jannat-Khah, Lindsey Reif, Serena P Koenig, Jean Wysler Domercant and 3 more

Abstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Margaret L McNairyCenter for Global Health, Weill Cornell Medical College, New York, New York, United States of America.ORCID http://orcid.org/0000-0001-7853-633X
Patrice JosephHaitian Study Group for Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti.
Michelle UnterbrinkDivision of General Medicine, Weill Cornell Medical College, New York, New York, United States of America.
Stanislas GalbaudHaitian Study Group for Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti.
Jean-Edouard MathonHaitian Study Group for Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti.
Vanessa RiveraHaitian Study Group for Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti.
Deanna Jannat-KhahDivision of General Medicine, Weill Cornell Medical College, New York, New York, United States of America.
Lindsey ReifCenter for Global Health, Weill Cornell Medical College, New York, New York, United States of America.
Serena P KoenigBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
Jean Wysler DomercantCenters for Disease Control and Prevention, Port-au-Prince, Haiti.
Warren JohnsonCenter for Global Health, Weill Cornell Medical College, New York, New York, United States of America.
Daniel W FitzgeraldCenter for Global Health, Weill Cornell Medical College, New York, New York, United States of America.
Jean W PapeCenter for Global Health, Weill Cornell Medical College, New York, New York, United States of America.

Funding

GHESKIO HIV Clinical Trial UnitUM1AI069421 · NIAID · GHESKIO CENTER · PI JEAN WILLIAM PAPE · 2012 to 2026
$23.6M
Same-Day HIV Testing and Treatment Initiation to Improve Retention in CareR01AI104344 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI KOENIG, SERENA PATRICIA · 2013 to 2015
$1.9M
Global Health Research Training in HIV and TuberculosisK24AI098627 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI FITZGERALD, DANIEL W · 2012 to 2022
$1.8M
CGH CDC HHS U2G GH000541CGH CDC HHS U2G GH000545NIAID NIH HHS K24 AI098627NIAID NIH HHS R01 AI104344NIAID NIH HHS UM1 AI069421
6 · The paper itself

Abstract

backgroundWe report patient outcomes after antiretroviral therapy (ART) initiation in a network of HIV facilities in Haiti, including temporal trends and differences across clinics, during the expansion of HIV services in the country.

methodsWe assessed outcomes at 12 months after ART initiation (baseline) using routinely collected data on adults (≥15 years) in 11 HIV facilities from July 2007-December 2013. Outcomes include death (ascertained from medical records), lost to follow-up (LTF) defined as no visit > 365 days from ART initiation, and retention defined as being alive and attending care ≥ 365 days from ART initiation. Outcomes were compared across calendar year of ART initiation and across facilities. Risk factors for death and LTF were assessed using Cox proportional hazards and competing risk regression models.

resultsCumulatively, 9,718 adults initiated ART with median age 37 years (IQR 30-46). Median CD4 count was 254 cells/uL (IQR 139-350). Twelve months after ART initiation, 4.4% (95% CI 4.0-4.8) of patients died, 21.7% (95% CI 20.9-22.6) were LTF, and 73.9% (95% CI 73.0-74.8) were retained in care. Twelve-month mortality decreased from 13.8% among adults who started ART in 2007 to 4.4% in 2013 (p<0.001). Twelve-month LTF after ART start was 29.2% in 2007, 18.7% in 2008, and increased to 30.1% in 2013 (p<0.001). Overall, twelve-month retention after ART start did not change over time but varied widely across facilities from 61.1% to 86.5%.

conclusionExpansion of HIV services across Haiti has been successful with increasing numbers of patients initiating ART and decreasing twelve-month mortality rates. However, overall retention has not improved, despite differences across facilities, suggesting additional strategies to improve engagement in care are needed.

Indexed as

Antiretroviral Therapy, Highly ActiveHealth Services AccessibilityAdultAnti-HIV AgentsCD4 Lymphocyte CountFemaleHaitiHIV InfectionsHumansLost to Follow-UpMaleMiddle AgedSurvival RateAnti-HIV Agents

Identifiers

PMID28437477
PMCPMC5402937

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.